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Abstract 
Atrial fibrillation (AF) is the most common type of arrhythmia. Current pharmacological 
treatment for AF is moderately effective and/or increases the risk of serious ventricular 
adverse effects. To avoid ventricular adverse effects, a new target has been 
considered, the small conductance calcium-activated K+  channels (KCa2.X, SK 
channels). In the heart, KCa2.X channels are functionally more important in atria 
compared to ventricles, and pharmacological inhibition of the channel confers atrial 
selective prolongation of the cardiac action potential and converts AF to sinus rhythm 
in animal models of AF. Whether antiarrhythmic drugs (AADs) recommended for 
treating AF target KCa2.X channels is unknown. To this end, we tested a large number 
of AADs on the human KCa2.2 and KCa2.3 channels to assess their effect on this new 
target using automated whole-cell patch clamp. Of the AADs recommended for 
treatment of AF only dofetilide and propafenone inhibited hKCa2.X channels, with no 
subtype selectivity. The calculated IC50 were 90 ± 10 µmol/l vs 60 ± 10 µmol/l for 
dofetilide and 42 ± 4 µmol/l vs 80 ± 20 µmol/l for propafenone (hKCa2.3 vs hKCa2.2). 
Whether this inhibition has clinical importance for their antiarrhythmic effect is 
unlikely, as the calculated IC50 values are very high compared to the effective free 
therapeutic plasma concentration of the drugs when used for AF treatment, 40,000-
fold for dofetilide and 140-fold higher for propafenone. 
Key words: atrial fibrillation; KCa2 channel; calcium-activated potassium channel; 
antiarrhythmic drug; automated patch clamp. 
 
 
Chemical compounds studied in this article 
Amiodarone hydrochloride (PubChem CID: 441325), disopyramide (PubChem CID: 
3114), dofetilide (PubChem CID: 71329), dronedarone (PubChem CID: 208898), 
flecainide (PubChem CID: 3356), ibutilide (PubChem CID: 60753), quinidine (PubChem 
CID: 441074), propafenone (PubChem CID: 4932), sotalol (PubChem CID: 5253) and 
vernakalant hydrochloride (PubChem CID: 9930048).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Introduction 
AF has become one of the most important public health problems in developed 
countries. The total lifetime risks for development of AF are 1 in 4 for 40 years age 
people and older (Lloyd-Jones et al., 2004). Furthermore,  it is expected that by 2030, 
only in Europe, a total of 14 - 17 million people will have AF and 120,000 - 215,000 new 
cases will appear every year (Zoni-Berisso et al., 2014). Therefore, it is important to 
have effective and safe therapeutic strategies to treat patients with AF.  
Over the past years, a number of drugs have been developed for rhythm control 
therapy and treatment of AF (Waks and Zimetbaum, 2016). Unfortunately, these drugs 
are only moderately effective, have many adverse effects and/or may trigger 
ventricular arrhythmias. Even recently approved drugs, like vernakalant, have limited 
effects on the treatment of AF and efficacy of the compound is drastically reduced 
after just a few days of consistent atrial fibrillation (Tsuji and Dobrev, 2013). Therefore, 
it is important to find new atrial selective targets for AF treatment. 
One promising new target is the small conductance calcium-activated potassium 
channel (KCa2.X or SK channel). This ion channel plays an important role on the late 
repolarization phase of especially atrial cardiomyocytes and its inhibition results in the 
prolongation of the effective refractory period (Diness et al., 2010), a strategy that has 
been used for the development of class III antiarrhythmic drugs (Schmitt et al., 2014). 
Moreover, this protein is functionally more important  in atria when compared to 
ventricles (Xu et al., 2003), which could help avoid possible ventricular adverse effects. 
It has also been demonstrated that pharmacological inhibition of the KCa2.X channel 
confers atrial selective prolongation of cardiac action potential and converts AF to 
sinus rhythm in a number of small and large animal models (Haugaard et al., 2015; Qi 
et al., 2014; Skibsbye et al., 2011). 
Whether antiarrhythmic drugs (AAD) recommended for treating AF target KCa2.X 
channels is unknown. To this end, we tested a large number of AADs (Table 1) on the 
human KCa2.X channels to assess their effect on this new target and its clinical 
significance. 
 
2. Materials and methods 
2.1. Cell culture 
Two different stable HEK293 cell lines expressing one specific subtype of the human 
KCa2 channel, either KCa2.2 or KCa2.3, obtained from NeuroSearch A/S (Ballerup, 
Denmark) (Strøbæk et al., 2004), were used to conduct the experiments. The cells 
were cultured in Dulbecco’s modified Eagle’s medium (DMEM1965, ThermoFisher, 
USA) supplemented with 2.2 g/l NaHCO3, 5.96 g/l HEPES, 10 ml/l Glutamax (Gibco, 
USA), 10% foetal bovine serum (Biowest, France), 100 U/ml of penicillin/streptomycin 
(Sigma, Germany) and 100 µg/ml geneticin (Gibco, USA) in T175 flasks. On the day of 
the experiment, when cells were 80-90% confluent, 1 ml of Detachin™ (Amsbio, United 
Kingdom) was used to detach the cells after being washed with free calcium and 
magnesium phosphate-buffered saline. Then, the cells were resuspended in 5 ml of 
serum-free DMEM media containing 0.04 mg/ml soy bean trypsin inhibitor (Sigma, 
Germany) and 25 mmol/l HEPES buffer (Sigma, Germany). 
2.2. Solutions and drugs 
Whole cell patch-clamp experiments were conducted using symmetrical K+ solutions. 
The extracellular solution contained 0.1 mmol/l CaCl2, 3 mmol/l MgCl2, 150 mmol/l KCl, 
10 mmol/l HEPES and 10 mmol/l glucose (pH = 7.4 and 285-295 mOsm) and the 
intracellular solution contained 8.106 mmol/l CaCl2, 1.167 mmol/l MgCl2, 10 mmol/l 
EGTA, 150 mmol/l KCl, 10 mmol/l HEPES, 31.25/10 mmol/l KOH/EGTA and 15 mmol/l 
KOH (pH = 7.2). Final free Ca2+ concentration was calculated to 400 nmol/l as 
previously described (Strobaek et al., 2006). The osmolarity of the intracellular solution 
was adjusted using sucrose (Sigma, Germany) to match the extracellular solution.  
Bicuculline methiodide, propafenone, quinidine, sotalol, flecainide, dofetilide, 
dronedarone, disopyramide and ibutilide were purchased from Sigma (Germany) and 
amiodarone hydrochloride was purchased from Tocris (United Kingdom) in their solid 
forms. The drugs were solubilized in pure dimethyl sulfoxide (Sigma, Germany) at a 
stock concentration of 10 mmol/l and stored at -20°C. On the day of the experiment, 
aliquots were diluted to the desired concentration in the extracellular solution. 
Vernakalant was purchased as the pharmaceutical preparation Brinavess 20 mg/ml 
(Cardiome, United Kingdom) and diluted at the day of the experiment to the desired 
concentrations in the extracellular solution to conduct the experiments with 
vernakalant hydrochloride.  
2.3. Electrophysiology 
Whole-cell experiments were conducted using the automated patch-clamp platform 
QPatch 16 (Sophion, Denmark). After breaking into the cell and establishing a giga seal, 
a first application of extracellular solution (saline) was applied. This application was 
followed by the KCa2.X inhibitor bicuculline (100 µmol/l), used as positive control for 
functional channel expression. Bicuculline was washed off with two more saline 
applications before applying the test drug. The last saline application prior to the test 
drug was used as baseline. After this, the test drug was applied at six increasing 
concentrations at a time scale that allowed for a potential steady-state in current 
reduction. Finally, after washing twice with saline, the experiment ended with 
application of bicuculline (100 µmol/l). The different steps of the protocol are 
illustrated in Fig. 1. Currents were elicited using 200 ms voltage ramps ranging from -
80 mV to +80 mV from a holding potential of 0 mV and were applied every 2 s with a 
sample rate of 10 kHz. To avoid background noise, the recorded signals were filtered 
using a Bessel filter with a cut-off frequency of 3 kHz. Series resistance compensation 
was set at 80%. 
2.4. Data analysis and statistics 
Current amplitudes were measured at -80 mV, and the mean of the last three 
recordings during each application was used for further analysis. To calculate changes 
in relative current, the mean values were normalized using the last saline application 
prior to applying test compound as baseline and the first bicuculline injection as 
reference for total inhibition of the channel. The data were then plotted and fitted 
using the following equation on GraphPad Prism 7: Y=Ymin+(Ymin+Ymax)/(1+10
X-logIC50), 
where Y is the normalized measured current, X is the logarithm of the dose of the 
tested drug and IC50 the drug concentration needed to inhibit 50% of the current. In all 
cases a Hill slope of -1.0 was presumed. Individual IC50 values were calculated for each 
experiment and then used to obtain the final mean ± S.E.M. 
Correction for baseline drift was applied if applicable, using the QPatch software and 
the bicuculline applications at the beginning and the end of the experiment as 
references.  
Student’s t-tests were used to determine subtype selectivity of test drugs. 
 
3. Results 
3.1. Amiodarone, disopyramide, dronedarone, flecainide, ibutilide, quinidine, sotalol 
and vernakalant have no effect on the hKCa2.3 channel. 
Currents were recorded from HEK cells stably expressing hKCa2.3 using an automated 
patch clamp system. In symmetrical intra- and extracellular K+  concentrations, hKCa2.3 
currents displayed a characteristic inwardly rectifying current-voltage relationship and 
were inhibited by bicuculline (Fig. 1). A first screening of the AADs was conducted on 
the hKCa2.3 channel. For each drug we tested six different concentrations, starting at 
0.1 µmol/l and finishing at 30 µmol/l. In the case of amiodarone the used 
concentrations were between 0.3 µmol/l and 100 µmol/l (Fig. 2). 
Amiodarone (n = 6), disopyramide (n = 8), dronedarone (n = 5), flecainide (n = 6), 
ibutilide (n = 5), quinidine (n = 5), sotalol (n = 5) and vernakalant (n = 5) had no effect 
on the hKCa2.3 current (Fig. 2). Only dofetilide and propafenone showed 
concentration-dependent inhibition at the highest concentrations on the hKCa2.3 and 
therefore were selected for further investigation.  
3.2. Dofetilide and propafenone are weak inhibitors of both hKCa2.3 and hKCa2.2 with 
no subtype selectivity. 
In order to obtain a complete inhibition curve for dofetilide and propafenone, a second 
round of experiments was conducted using higher concentrations, starting at 1 µmol/l 
and finishing at 300 µmol/l (Fig. 3). 
As can be seen in Fig. 3A and Fig. 3B, dofetilide and propafenone inhibited the hKCa2.3 
current in a dose dependent manner. The effect started at 10 µmol/l for both drugs 
and reached nearly complete inhibition at 300 µmol/l. In the case of propafenone, a 
pronounced drift of the current was observed at the beginning of each new dose 
application, even after baseline correction. This drift, which was specific for 
propafenone, stabilized at the end of each application and it was less pronounced as 
the concentration of the drug was increased. The calculated IC50 for dofetilide and 
propafenone were 90 ± 10 µmol/l (n = 13) and 42 ± 4 µmol/l (n = 8) for hKCa2.3, 
respectively (Fig. 4). To address if dofetilide or propafenone displayed subtype 
selective effects, we also tested both drugs on HEK cells stably expressing the hKCa2.2 
channel. Dofetilide and propafenone were applied on the hKCa2.2 expressing cells at 
the same concentrations and using the same protocol as described for hKCa2.3 channel.  
Both drugs were also able to inhibit hKCa2.2 currents in a concentration dependent 
manner (data not shown). In this case, the effect of dofetilide started at a lower dose 
of 3 µmol/l. Inhibition by propafenone was first observed at 10 µmol/l, as seen in 
hKCa2.3. On the hKCa2.2 channel the characteristic drift of propafenone was also 
present at the beginning of every dose application and it stabilized as the dose of the 
drug was increased. The calculated IC50 for dofetilide and propafenone on the hKCa2.2 
channel were 60 ± 10 µmol/l (n = 13) and 80 ± 20 µmol/l (n = 6), respectively. Neither 
dofetilide (p = 0.1915) nor propafenone (p = 0.1816) showed any subtype selectivity. 
Due to the apparent weak binding and fast kon and koff of dofetilide and propafenone 
(Fig. 4), only current measurements corresponding to steady states, were considered 
to calculate the IC50. 
 
4. Discussion 
Despite being the most common type of arrhythmia, safe and effective AF treatment 
continues to be an unmet medical need. It is therefore important to find new 
strategies and targets to treat this increasingly prevalent disease. It has been revealed 
that both chronic (Voigt et al., 2012) and paroxysmal AF (Voigt et al., 2014) are 
associated with abnormal Ca2+-handling, like spontaneous sarcoplasmic reticulum Ca2+-
release and delayed after depolarizations. These events may modulate and activate 
other ion channels, such as KCa2.x, resulting in shorter APDs and increased AF 
vulnerability. Therefore, the KCa2.X channel is a promising new atrial selective target 
whose inhibition has proven to be efficacious in both  cardioversion and prevention of 
new AF episodes in a number of animal models (Goldin Diness et al., 2011; Haugaard 
et al., 2015; Qi et al., 2014; Skibsbye et al., 2011). The identification and development 
of novel drugs targeting the cardiac KCa2.X channels and the understanding of their 
role in cardiac function may end up in a whole new AF therapy. AADs recommended 
for treating AF target a number of ion channels and receptors, but whether they can 
inhibit KCa2.X channels has not been systematically tested until now. Amiodarone has 
previously been reported to inhibit KCa2.2 channels expressed in HEK-293 cells (Turker 
et al., 2013), but this study is the first to test a large number of the recommended 
AADs for treatment of AF on the hKCa2 channel. Ten AADs at six different 
concentrations ranging between 0.1 – 30 µmol/l on the hKCa2.3 channel were tested. 
From this first screening, only dofetilide and propafenone showed concentration-
dependent inhibition of the hKCa2.3 current. Amiodarone, disopyramide, dronedarone, 
flecainide, ibutilide, quinidine, sotalol and vernakalant had no effect on the hKCa2.3 
current at any of the tested concentrations. The study published by Turker et al (2013) 
characterized the effect of amiodarone on the hKCa2.2 channel and showed that 
amiodarone was able to inhibit the IKCa current with an IC50 of 3 µmol/l when 
intracellular free Ca2+ concentration was 1 µmol/l. Our experiments failed to show any 
effect of amiodarone at any of the tested concentrations on any of the KCa2 subtypes 
(data not shown for hKCa2.2). This contradiction might be explained by the strong 
calcium dependent effect of amiodarone on the hKCa2 channel, which was also 
reported in Turker’s work. According to the mentioned study, 30 µmol/l amiodarone 
were able to inhibit around 80% of the IKCa when the intracellular Ca
2+ concentration 
was 1 µmol/l, but the effect dropped drastically when Ca2+ concentration was 
decreased. As they state in the discussion of their work, it is possible that 400 nmol/l 
of intracellular Ca2+ concentration (Desk and Williams, 1994), the one chosen for our 
screening, is not enough to assess the inhibitory effect of amiodarone at 10 µmol/l, 
although we were not able to see any significant effect at higher concentrations 
neither. Another important difference between Turker’s work and the present study 
are the K+ concentrations used for the extracellular and intracellular solutions. While 
Turker used physiological K+ concentrations for their experiments, in this study, we 
used symmetrical K+ solutions. In any case, it is improbable that the antiarrhythmic 
effect of amiodarone is partly due to its hKCa2 inhibition because, in a clinical situation, 
the effective free therapeutic plasma concentration of amiodarone for AF treatment is 
below 1 nmol/l (see Table 1), 3,000 times lower than the previously reported IC50.  
The second round of experiments included dofetilide and propafenone. The selected 
AADs were tested at a higher concentration range (1 – 300 µmol/l) in order to obtain 
complete inhibition curves. Moreover, the same experiments were conducted on both 
hKCa2.3 and hKCa2.2 to assess possible subtype selectivity. The calculated IC50 for 
dofetilide and propafenone were 60 ± 10 µmol/l and 80 ± 20 µmol/l for hKCa2.2, and 90 
± 10 µmol/l and 42 ± 4 µmol/l for hKCa2.3, respectively. Neither dofetilide nor 
propafenone showed any subtype selectivity. In the case of propafenone, a rapid “run 
up” of current was observed shortly after the application of the drug in all the 
performed experiments. This run up stabilizes with time and is less pronounced when 
the concentration of propafenone is increased. It could be speculated that this 
phenomenon might be explained by an extremely fast kon and koff of propafenone on 
the hKCa2 channel. The fast binding of propafenone on the channel is followed by the 
also rapid unbinding of the drug, which is depicted as a current run up on the current-
time plots, until equilibrium is reached and the current stabilized. The higher the 
concentration, the faster the equilibrium was reached, reducing the run up of the 
current. For this reason, only the measurements corresponding to the steady state 
were considered in order to calculate the IC50. 
Although dofetilide and propafenone were able to inhibit both hKCa2.2 and hKCa2.3 
currents, it is highly improbable that this effect has any importance for their 
antiarrhythmic effects observed in the clinic. The calculated IC50 for both drugs are 
extremely high when compared to the highest effective therapeutic free plasma 
concentration used for AF treatment (see Table 1), 40,000-fold and 140-fold higher for 
dofetilide and propafenone, respectively. 
5. Conclusions  
Ten of the most common AADs used for the treatment of AF have been screened to 
assess their effect on the hKCa2 channel using whole-cell automated patch-clamp. Only 
two of them, dofetilide and propafenone, were able to weakly inhibit both hKCa2.2 and 
hKCa2.3 in a concentration-dependent fashion with no subtype selectivity. Since the 
IC50 of the drugs on the hKCa2 channel is very high when compared to their effective 
therapeutic free plasma concentration, it is unlikely that this inhibition has any clinical 
relevance for their antiarrhythmic effect. More efforts on the development of new 
effective and safe drugs selectively targeting the KCa2.X channels should be considered 
to improve AF treatment.  
5.1. Limitations of the study 
Manual patch clamp is the gold standard for electrophysiology. However automated 
patch clamp allows for higher throughput. This technique is successfully and 
continuously being used for primary and secondary drug screening on a great range of 
ion channels, including calcium-activated potassium channel (Coleman et al., 2014). 
Moreover, experiments on automated patch clamp systems are highly reproducible 
and comparable to the results obtained by the manual patch clamp technique 
(Korsgaard et al., 2009).  
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Figure captions 
Fig. 1. Representative current-time plot showing the steps included in the screening 
protocol. The first reference application (100 µmol/l bicuculline) was used to normalize 
current inhibtion. The last saline application prior to the first application of the drug 
was used as baseline. Only measurements correspondoding to steady states were 
considered to calculate IC50. 
Fig. 2. Voltage ramp protocol used to measure the IKCa currents (top left). 
Representative current-voltage graph (top right) showing the measured IKCa current 
(grey line) and its inhibition by 100 µmol/l bicuculline (black line). Effect of amiodarone 
(n = 6), disopyramide (n= 8), dronedarone (n = 5), flecainide (n = 6), ibutilide (n = 5), 
quinidine (n = 5), sotalol (n = 5) and vernakalant (n = 5) on hKCa2.3 (mean ± S.E.M.). 
Increasing concentrations of AADs were tested on hKCa2.3, starting from 0.1 µmol/l 
and up to 30 µmol/l. In the case of amiodarone, the starting concentration was 0.3 
µmol/l and the highest concentration 100 µmol/l. 
Fig. 3. Representative current-time plots of A) dofetilide and B) propafenone inhibition 
on the hKCa2.3 (left) and their current-voltage recordings (right).  
Fig. 4. Inhibition curves of dofetilide and propafenone on hKCa2.2 (grey lines) and 
hKCa2.3 (black lines). None of the compounds showed any subtype selectivity. 
 
 
 
 
 
Table 1 list of tested AADs, current or channels/receptors blocked by the drug and 
their effective free therapeutic plasma concentration for AF treatment. 
Drug Current/channel/receptors (Waks 
and Zimetbaum, 2016) 
Effective free therapeutic plasma 
concentration (nmol/l) 
Amiodarone INa, IKr, IKs, IKur, ICaL, IKAch, Ito, α, β  0.3 - 0.6 (Redfern et al., 2003) 
Disopyramide IKr, INa, IKAch  215 - 800 (Redfern et al., 2003) 
Dofetilide IKr  0.4 - 1.5 (Redfern et al., 2003) 
Dronedarone INa, IKr, IKs, IK1, ICaL, IKAch, α, β  150 – 300
1 (Patel et al., 2009) 
Flecainide INa  400 – 900 (Redfern et al., 2003) 
Ibutilide IKr  0.8 - 150 (Redfern et al., 2003) 
Propafenone INa, β  30 - 300 (Redfern et al., 2003) 
Quinidine IKr, IKs, Ito, IKATP, ICaL, INa, IKAch  750 – 3,000 (Redfern et al., 2003) 
Sotalol IKr, β  2,000 – 15,000 (Redfern et al., 2003) 
Vernakalant IKur  1,000 – 10,000 (Fedida, 2007) 
1steady state plasma concentration after 7 days. 
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